Nilotinib and Imatinib Utilization in Iran over 14 years

Nilotinib and Imatinib Utilization in Iran over 14 years

Background: Tyrosine Kinase Inhibitors (TKIs) are drugs of choice for Chronic Myeloid Leukemia (CML) treatment. CML healthcare costs greatly exceed of other haematological malignancies treatment mostly due to TKIs. There are several generic and brand preparations of imatinib and nilotinib, the only...

Full description

Bibliographic Details
Main Authors:	Ava Mansouri, Kimia Hirbod, Maryam Taghizadeh-Ghehi, Aarefeh Jafarzadeh Kohneloo, Mohammad Solduzian, Molouk Hadjibabaie
Format:	Article
Language:	English
Published:	Research Center for Rational Use of Drugs (RCRUD) 2020-12-01
Series:	Journal of Pharmaceutical Care
Subjects:	Nilotinib Imatinib Chronic Myeloid Leukemia Insurance Coverage Drug Prescriptions Drug Utilization Review
Online Access:	https://jpc.tums.ac.ir/index.php/jpc/article/view/378

Similar Items

Nilotinib after imatinib failure
by: Luca Pezzullo
Published: (2015-10-01)

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01)

Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01)

Complete molecular response induced by nilotinib in a patient previously treated with imatinib, nilotinib and dasatinib
by: Giuseppe Pietrantuono
Published: (2015-10-01)

Different response to imatinib and nilotinib in relationship with the time of administration
by: Paolo Danise
Published: (2015-10-01)

Nilotinib therapy after resistance and intolerance to imatinib in CML patient with trisomy of the chromosome 8
by: Antonella Russo Rossi
Published: (2015-10-01)

Nilotinib efficacy in a patient resistant to imatinib
by: Luigia Luciano
Published: (2015-10-01)

Nilotinib therapy after resistance to imatinib
by: Raffaele Porrini, et al.
Published: (2015-10-01)

Efficacy of nilotinib in a patient relapse after 9 years of imatinib treatment and in stable complete cytogenetic response
by: Marzia Defina
Published: (2015-10-01)

Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01)

Treatment with nilotinib after cytogenetic relapse at 12 months in a patient in chronic phase with sub-optimal response to imatinib
by: Massimo Breccia
Published: (2015-10-01)

Efficacy of nilotinib in second line in an elderly patient with CML, suboptimal response and multiple comorbidities
by: Carmen Tomaselli
Published: (2015-10-01)

Nilotinib therapy in an imatinib intolerant chronic myeloid leukemia patient with pulmonary severe hypertension
by: Mario Annunziata
Published: (2015-10-01)

Rapid and sustained molecular response to nilotinib in a patient with sub-optimal response to imatinib
by: Mario Annunziata
Published: (2015-10-01)

Efficacy and safety of nilotinib as third-line therapy in an elderly patient with CML
by: Giovanni Caocci, et al.
Published: (2015-10-01)

Successful management of pregnancy and hepatic toxicity in a CML female patient treated with nilotinib : a case report and a review
by: Domenico Santorsola, et al.
Published: (2015-02-01)

Early switch to nilotinib in a case of non-optimal response to imatinib
by: Alessandra Iurlo, et al.
Published: (2015-10-01)

A case of double leukemia: chronic myeloid leukemia intolerant to imatinib and chronic lymphocytic leukemia
by: Miriana Rocchi
Published: (2015-10-01)

Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up
by: Mozafar Aznab, et al.
Published: (2021-01-01)

Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature
by: Asiyeh Amouei, et al.
Published: (2021-04-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

p53 Gene (NY-CO-13) Levels in Patients with Chronic Myeloid Leukemia: The Role of Imatinib and Nilotinib
by: Hayder M. Al-kuraishy, et al.
Published: (2018-01-01)

Efficacy of nilotinib in a patient in non-optimal response after imatinib treatment but in reduced compliance to the new drug
by: Francesca Sassolini
Published: (2015-10-01)

Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib
by: Sabina Russo, et al.
Published: (2015-10-01)

Chronic myeloid leukemia: successful therapy with nilotinib in a young patient with high Sokal risk and in sub-optimal response with imatinib
by: Fausto Palmieri
Published: (2015-10-01)

LONG-TERM RESULTS OF TARGET THERAPY WITH FIRST AND * SECOND-LINE TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: L. L. Vysotskaya, et al.
Published: (2016-02-01)

Nilotinib is effective and well tollerate in patients with multiple comorbidities
by: Carmen Fava, et al.
Published: (2015-10-01)

Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option
by: Hyun Yang, et al.
Published: (2020-07-01)

Use of nilotinib in the diabetic patient
by: Carmen Tomaselli
Published: (2015-10-01)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
by: Hassan A. Al-Jafar, et al.
Published: (2015-03-01)

Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
by: Ryosuke Nakahara, et al.
Published: (2019-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Treatment outcome of 100 chronic myeloid leukemia patients using nilotinib as the 2nd line therapy
by: Yaseen M Taher, et al.
Published: (2018-01-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Diversity of Physicians’ Handwriting and Name Stamp in Chemotherapy Prescriptions: Potential Target for Fraud
by: Asiyeh Amouei, et al.
Published: (2018-02-01)

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
by: Lu Yu, et al.
Published: (2018-08-01)

Prescribing pattern and prescription-writing quality of antineoplastic agents in the capital city of a middle-income developing country
by: Maryam Taghizadeh-Ghehi, et al.
Published: (2018-01-01)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
by: Husam N. Al-Dubai, et al.
Published: (2020-06-01)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
by: Yoo Jin Na, et al.
Published: (2021-03-01)

Nilotinib early switch efficacy in non-optimal responder CML patient after first line imatinib treatment
by: Ferdinando Porretto
Published: (2015-10-01)